Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study

IntroductionMetabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and is strongly associated with obesity, insulin resistance, and systemic inflammation. Tirzepatide, a dual GIP and GLP-1 receptor agonist, has shown significant effects on...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Martina Galasso, Ludovica Verde, Renato Patrone, Giovanni Ragozzino, Giuseppe Annunziata, Annamaria Colao, Luigi Barrea, Giovanna Muscogiuri
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2026-07-01
Edice:	Frontiers in Endocrinology
Témata:	fatty liver index (FLI) Inflammation metabolic dysfunction–associated steatotic liver disease (MASLD) obesity tirzepatide
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fendo.2026.1855886/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!